Miron C, Chiriloiu C, Mustea A, Tănăsescu C, Balgiu N, Sulea M
Med Interne. 1984 Jan-Mar;22(1):55-60.
A group of 214 nonselected former patients with viral hepatitis of which 15 HBsAg negative and 62 HBsAg positive, was studied prospectively by following the evolutive variations between the first and second year after the acute phase of disease. In both groups the percentage of cured cases increased moderately but the evolutive process toward the chronic stage was observed to reappear in some of the cases apparently cured thus proving that the process of becoming chronic is not completed within 1 year after the acute phase. The percentage of chronic cases after HBsAg positive hepatitis is clearly higher than after HBsAg negative hepatitis the difference being more evident in active chronic hepatitis. The risk of becoming chronic is greater after HBsAg positive viral hepatitis with prolonged clinical forms and the HB antigen also persists longer in the serum. In conclusion the necessity of clinical and biologic control of all former patients with viral hepatitis for at least 2 years after the acute phase is strongly emphasized.
对一组214例未经挑选的既往病毒性肝炎患者进行了前瞻性研究，其中15例HBsAg阴性，62例HBsAg阳性。通过追踪疾病急性期后第一年和第二年之间的演变变化来进行研究。在两组中，治愈病例的百分比均适度增加，但在一些明显治愈的病例中，观察到向慢性阶段的演变过程再次出现，从而证明慢性化过程在急性期后1年内并未完成。HBsAg阳性肝炎后的慢性病例百分比明显高于HBsAg阴性肝炎后，这一差异在活动性慢性肝炎中更为明显。HBsAg阳性病毒性肝炎伴有迁延临床类型时，慢性化风险更大，且HB抗原在血清中持续存在的时间也更长。总之，强烈强调对所有既往病毒性肝炎患者在急性期后至少2年进行临床和生物学监测的必要性。
